

SAN DIEGO, Nov. 24, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [OREX](#)) , a biopharmaceutical company focused on the treatment of obesity, will announce results of the Light Study interim analysis on Monday, November 25, 2013 prior to market open. Following the announcement, Orexigen management will host a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).

The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 36202424. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application had been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com .

McDavid Stilwell Vice President, Corporate Communications & Business Development
858-875-8600

SOURCE Orexigen Therapeutics, Inc.

Written by Australian Business

RELATED LINKS <http://www.orexigen.com>